Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04044534 · ClinicalTrials.gov registry record · Phase 2
Intranasal Insulin for Posttraumatic Stress Disorder
A Phase 2 study of PTSD, sponsored by VA Connecticut Healthcare System.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT04044534 is a Phase 2 study of PTSD that is actively recruiting participants, run by VA Connecticut Healthcare System. The registered enrollment target is 20 participants, below the 302-participant average among 154 other PTSD trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04044534, a Phase 2 study of PTSD, is actively recruiting participants, sponsored by VA Connecticut Healthcare System.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate if intranasal insulin is effective in reducing PTSD symptoms.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Intranasal insulin
Study Locations (1)
Connecticut
- VA Connecticut Healthcare System - West Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-10-31 |
| Est. Completion | 2026-05-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04044534
The ClinicalTrials.gov registry entry for NCT04044534 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 302-participant average among 154 other PTSD trials with a reported enrollment target (93% lower). The listed sponsor is VA Connecticut Healthcare System, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with PTSD appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04044534 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT04044534 about?
NCT04044534 is a clinical study titled "Intranasal Insulin for Posttraumatic Stress Disorder". To evaluate if intranasal insulin is effective in reducing PTSD symptoms.
What is the current status of trial NCT04044534?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2024-10-31. Estimated completion is 2026-05-31.
What conditions does trial NCT04044534 study?
This clinical trial studies the following conditions: PTSD.
What interventions are being tested in trial NCT04044534?
The interventions under investigation include: Placebo (DRUG), Intranasal insulin (DRUG).
Who is sponsoring clinical trial NCT04044534?
This trial is sponsored by VA Connecticut Healthcare System, which has 26 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04044534 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for PTSD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Oxytocin to Enhance Integrated Treatment for AUD and PTSD
RECRUITING · Phase 2
-
MDMA-assisted Cognitive Processing Therapy Versus Cognitive Processing Therapy for Veterans With Severe Posttraumatic Stress Disorder
RECRUITING · Phase 2
-
Psilocybin With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring PTSD & Alcohol Use Disorder (AUD)
RECRUITING · Phase 2
-
Induction of Dreaming With EEG and Anesthesia for Post-traumatic Stress Disorder
RECRUITING · Phase 2
-
Glecaprevir/Pibrentasvir for Post-traumatic Stress Disorder
RECRUITING · Phase 2
-
Safety and Efficacy of Cannabidiol (CBD) for Symptoms of PTSD in Adults
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.